Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1 negative, experienced a prompt and exceptionally favorable response to pembrolizumab monotherapy. After cessation of treatment due to immune-relate...
Main Authors: | Bernard F. Hearon, Kyle N. Redelman, Georges C. Elhomsy, Dennis F. Moore, Jr. |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-12-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/512013 |
Similar Items
-
Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
by: Walid Shalata, et al.
Published: (2021-07-01) -
Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma
by: Yaru HUANG, et al.
Published: (2021-06-01) -
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab
by: Wambaka Ange Mampuya, et al.
Published: (2021-03-01) -
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
by: Joanne M. Mankor, et al.
Published: (2020-12-01) -
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
by: Benjamin Wadowski, et al.
Published: (2021-06-01)